NasdaqGM - Delayed Quote • USD
Applied Therapeutics, Inc. (APLT)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.14 | -0.17 | -0.72 | -0.39 |
| Low Estimate | -0.18 | -0.2 | -0.82 | -0.7 |
| High Estimate | -0.07 | -0.15 | -0.53 | -0.04 |
| Year Ago EPS | -0.18 | -0.37 | -1.42 | -0.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 4 |
| Avg. Estimate | 3.33M | -- | 7.73M | 71.99M |
| Low Estimate | -- | -- | 1.76M | 11.84M |
| High Estimate | 10M | -- | 17.2M | 144.58M |
| Year Ago Sales | 10.66M | -- | 9.99M | 7.73M |
| Sales Growth (year/est) | -68.80% | -- | -22.60% | 831.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.31 | -0.26 | -0.26 | -0.23 |
| EPS Actual | -0.18 | -0.37 | -0.47 | -0.34 |
| Difference | 0.13 | -0.11 | -0.21 | -0.11 |
| Surprise % | 41.90% | -42.30% | -80.80% | -47.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.14 | -0.17 | -0.72 | -0.39 |
| 7 Days Ago | -0.14 | -0.17 | -0.72 | -0.39 |
| 30 Days Ago | -0.12 | -0.17 | -0.71 | -0.33 |
| 60 Days Ago | -0.2 | -0.15 | -0.87 | -0.54 |
| 90 Days Ago | -0.23 | -0.15 | -0.98 | -0.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | APLT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 22.20% | -- | -- | 1.50% |
| Next Qtr. | 54.10% | -- | -- | 11.40% |
| Current Year | 49.30% | -- | -- | 5.20% |
| Next Year | 45.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | RBC Capital: Outperform to Outperform | 4/11/2024 |
| Initiated | RBC Capital: Outperform | 3/26/2024 |
| Maintains | UBS: Buy to Buy | 3/15/2024 |
| Maintains | UBS: Buy to Buy | 3/6/2024 |
| Initiated | Leerink Partners: Outperform | 2/22/2024 |
| Maintains | Citigroup: Buy to Buy | 2/16/2024 |
Related Tickers
EWTX Edgewise Therapeutics, Inc.
16.11
+2.94%
ELVN Enliven Therapeutics, Inc.
17.49
+0.69%
CGEM Cullinan Therapeutics, Inc.
18.89
+13.32%
SLNO Soleno Therapeutics, Inc.
39.34
-1.99%
ANNX Annexon, Inc.
4.4500
+0.23%
RLMD Relmada Therapeutics, Inc.
3.8600
-1.28%
ACLX Arcellx, Inc.
52.82
-2.98%
DYN Dyne Therapeutics, Inc.
24.98
-1.81%
VTYX Ventyx Biosciences, Inc.
4.2400
-2.53%
KRYS Krystal Biotech, Inc.
159.05
-1.85%